Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias-Reference-Cited by-同舟云学术

Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias

Published:2021-12 Issue: Volume:111 Page:106690
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Kota Vamsi,Brümmendorf Tim H.^ORCID,Gambacorti-Passerini Carlo,Lipton Jeff H.,Kim Dong-Wook,An Fiona,Leip Eric,Crescenzo Rocco J.,Ferdinand Roxanne,Cortes Jorge E.^ORCID

Funder

Novartis

Ariad Pharmaceuticals

Bristol-Myers Squibb

Pfizer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference16 articles.

1. Bosulif® (bosutinib) Prescribing Information;Pfizer Inc,2015

2. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors;Gambacorti-Passerini;Am. J. Hematol.,2015

3. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial;Cortes;J. Clin. Oncol.,2012

4. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial;Brummendorf;Br. J. Haematol.,2015

5. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib;Cortes;Blood,2011

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial;Leukemia;2024-08-20

2. A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial);International Journal of Hematology;2024-08-13

3. Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia;Annals of Hematology;2024-07-18

4. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

5. Advances in the Treatment of Chronic Myeloid Leukemia;Recent Patents on Anti-Cancer Drug Discovery;2024-02